Cannabis and Thought Disorder in Schizophrenia

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

63 participants

Study Classification

INTERVENTIONAL

Study Start Date

2018-12-07

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Recent studies have suggested a strong relationship between cannabis use and the level of thought disorder in subjects with schizophrenia. Moreover, the level of thought disorder has been associated with an increased functional connectivity between the temporal lobe and the Putamen. However, the brain mechanisms underlying these two relationships are still poorly known. Better understanding these mechanisms is important to improve patients' care, in particular among treatment-resistant patients.

The objective of the CANDI study consists of assessing whether the level of cannabis use in patients with schizophrenia modulates the level of thought disorder via a modulation of the functional connectivity between the temporal lobe and the Putamen. Analyses will be controlled for the composition of cannabis, in particular the tetrahydrocannabinol / cannabidiol ratio.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Impact of Cannabis Consumption on Psychotic Symptoms and Reality Monitoring in Patients With Schizophrenia: a Real-life Study

NCT07309159

Schizophrenia

NOT_YET_RECRUITING PHASE1/PHASE2

Effect of Motivational Therapy on Schizophrenia With Cannabis Misuse

NCT00798109

Schizophrenia Cannabis Dependence, Continuous

COMPLETED NA

Combination of Dronabinol and Clonidine for Cannabis Dependence in Patients With Schizophrenia

NCT01598896

Cannabis Dependence Marijuana Dependence

TERMINATED PHASE2/PHASE3

Effects of Repetitive Transcranial Magnetic Stimulation (rTMS) on Cannabis Use and Cognitive Outcomes in Schizophrenia

NCT03189810

Repetitive Transcranial Magnetic Stimulation (rTMS) Schizophrenia Cannabis Use Disorder +1 more

COMPLETED NA

Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis

NCT03883360

Schizophrenia Spectrum Disorders Cannabis Use

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

25 subjects with schizophrenia and current cannabis use will be recruited in the experimental group. The control group will consist of 25 subjects with schizophrenia but with no cannabis use.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Schizophrenia

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NON_RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Cannabis users

Subjects of this group have to meet the DSM-5 criteria for schizophrenia and smoke cannabis at least two days per week for every week of the past month. They have to exhibit negative urine screen for any substance except benzodiazepines and cannabis.

Group Type EXPERIMENTAL

Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships

Intervention Type OTHER

To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.

Non- cannabis users (control group)

Subjects of this group have to meet the DSM-5 criteria for schizophrenia and have to report no cannabis use over the previous month, and exhibit negative urine screen for any substance except benzodiazepines.

Group Type ACTIVE_COMPARATOR

Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships

Intervention Type OTHER

To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Cannabis and thought disorder in schizophrenia:clinical and neuroimaging relationships

To investigate whether the level of cannabis use in schizophrenic patients influences the symptoms of psychic disorganization via modulation of cerebral connectivity between the temporal lobe and the putamen.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged between 18 and 65
* Meeting the DSM-5 criteria for schizophrenia
* "Cannabis user" group: - Smoking at least two days per week during the previous months
* Displaying positive urine screen for cannabis
* "Non-cannabis user" group: - No episode of cannabis smoking during the previous month
* Negative urine screen for cannabis + no lifetime criteria for cannabis use disorder (assessment by an addiction specialist).

Exclusion Criteria

* Current criteria for axis-1 psychiatric disorder other than schizophrenia
* Current criteria for any other substance use disorder except for nicotine use disorder
* Any contraindication for MRI
* Tutorship or curatorship
* Pregnant or lactating woman

Minimum Eligible Age

18 Years

Maximum Eligible Age

65 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No